These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19285012)

  • 1. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
    Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
    Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-Based Multiplexed Assay for Identifying SH2 Domain Antagonists.
    Asai A; Takakuma K
    Methods Mol Biol; 2017; 1555():351-356. PubMed ID: 28092042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
    Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
    Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening.
    Hao W; Hu Y; Niu C; Huang X; Chang CP; Gibbons J; Xu J
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4988-92. PubMed ID: 18768317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
    Park IH; Li C
    J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the binding of high affinity phosphopeptides to Stat3.
    McMurray JS
    Biopolymers; 2008; 90(1):69-79. PubMed ID: 18058821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.
    Schust J; Sperl B; Hollis A; Mayer TU; Berg T
    Chem Biol; 2006 Nov; 13(11):1235-42. PubMed ID: 17114005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New syntheses of tetrazolylmethylphenylalanine and O-malonyltyrosine as pTyr mimetics for the design of STAT3 dimerization inhibitors.
    Dourlat J; Valentin B; Liu WQ; Garbay C
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3943-6. PubMed ID: 17509878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An RNA biding protein, Y14 interacts with and modulates STAT3 activation.
    Ohbayashi N; Taira N; Kawakami S; Togi S; Sato N; Ikeda O; Kamitani S; Muromoto R; Sekine Y; Matsuda T
    Biochem Biophys Res Commun; 2008 Aug; 372(3):475-9. PubMed ID: 18503751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.
    Takakuma K; Ogo N; Uehara Y; Takahashi S; Miyoshi N; Asai A
    PLoS One; 2013; 8(8):e71646. PubMed ID: 23977103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
    Yu W; Xiao H; Lin J; Li C
    J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor.
    Coleman DR; Ren Z; Mandal PK; Cameron AG; Dyer GA; Muranjan S; Campbell M; Chen X; McMurray JS
    J Med Chem; 2005 Oct; 48(21):6661-70. PubMed ID: 16220982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of Stat3 inhibition in sparse vs confluent normal and breast cancer cells.
    Anagnostopoulou A; Vultur A; Arulanandam R; Cao J; Turkson J; Jove R; Kim JS; Glenn M; Hamilton AD; Raptis L
    Cancer Lett; 2006 Oct; 242(1):120-32. PubMed ID: 16377083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.
    Zhang X; Yue P; Fletcher S; Zhao W; Gunning PT; Turkson J
    Biochem Pharmacol; 2010 May; 79(10):1398-409. PubMed ID: 20067773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains.
    Gunning PT; Katt WP; Glenn M; Siddiquee K; Kim JS; Jove R; Sebti SM; Turkson J; Hamilton AD
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1875-8. PubMed ID: 17336521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
    Furtek SL; Backos DS; Matheson CJ; Reigan P
    ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear protein IkappaB-zeta inhibits the activity of STAT3.
    Wu Z; Zhang X; Yang J; Wu G; Zhang Y; Yuan Y; Jin C; Chang Z; Wang J; Yang X; He F
    Biochem Biophys Res Commun; 2009 Sep; 387(2):348-52. PubMed ID: 19595668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new small-molecule Stat3 inhibitor.
    McMurray JS
    Chem Biol; 2006 Nov; 13(11):1123-4. PubMed ID: 17113993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the signal transducer and activator of transcription-3 (STAT3) signaling pathway by 4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxylic acid esters.
    Xu J; Cole DC; Chang CP; Ayyad R; Asselin M; Hao W; Gibbons J; Jelinsky SA; Saraf KA; Park K
    J Med Chem; 2008 Jul; 51(14):4115-21. PubMed ID: 18578470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.
    Page BD; Khoury H; Laister RC; Fletcher S; Vellozo M; Manzoli A; Yue P; Turkson J; Minden MD; Gunning PT
    J Med Chem; 2012 Feb; 55(3):1047-55. PubMed ID: 22148584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.